We are pleased to announce that our latest medical project has successfully passed the formal evaluation stage of a competition for entrepreneurs to conduct research in the field of medical devices and in vitro diagnostic solutions (2024/ABM/06/KPO). As a result, our proposal has been qualified for substantive evaluation, which is an important step towards obtaining financial support.

It is worth noting that only 13 projects out of all the applications submitted qualified for this stage. Importantly, the total amount of funding requested does not exceed the total budget allocated for the competition. This means that every project that has passed the formal evaluation has a very high chance of receiving financial support.

The submitted project, entitled “Development of a platform for automatic analysis of laboratory test results based on the Dbam o Siebie Smart LAB solution,” is an ambitious undertaking aimed at developing innovative technologies to support medical diagnostics. The innovation and potential of this project are in line with the strategic needs of the medical device and in vitro diagnostic solutions market, which further emphasizes its importance for the rapidly growing medtech sector.
We would like to thank everyone involved in the preparation of this project. We look forward to the next stages of the evaluation!

The Management Board of the Company announces that, under the framework agreement concluded with PKO Życie Towarzystwo Ubezpieczeń S.A. and PKO Towarzystwo Ubezpieczeń S.A. concerning the provision of a team of IT specialists and the performance of services in the field of analysis, design, implementation, and development of IT systems, the Company has received another order.

The new order provides for an extension of the scope of existing work, which the Company will commence in January 2025. The work will be carried out in accordance with the cooperation models set out in the framework agreement: Time & Material and Fixed Price.

The Management Board emphasizes that the extension of cooperation with the Client is a testament to the high quality of the services provided and confirmation of the contract’s potential. In the opinion of the Management Board, it also represents an opportunity for further development of cooperation in the future.

The Management Board of Proacta S.A. with its registered office in Warsaw hereby announces that on December 16, 2024, a framework agreement was signed with Colway J. Zych N. Zych Spółka Jawna with its registered office in Koleczkowo.

The signed agreement regulates the general terms and conditions of cooperation in the following areas:

• – provision of a team of IT specialists
  • – provision of services related to the analysis, design, implementation, maintenance, and development of IT systems

The cooperation will be conducted in two models:

• – Time & Material
  • – Fixed Price

The agreement was concluded for an indefinite period, with the possibility of termination with one month’s notice.

The issuer considered this information to be confidential due to its potential impact on the future financial and economic situation of the company.

We are pleased to announce that Proacta S.A. has signed a letter of intent with Szpital Czerniakowski Sp. z o.o. in Warsaw. Our cooperation will focus on creating innovative solutions based on medical data analysis and the use of artificial intelligence to build analytical and predictive models.

Szpital Czerniakowski has expressed interest in our technologies in the areas of early disease detection, patient health education, and the implementation of preventive measures.

Together, we intend to develop projects that will contribute to improving the quality of healthcare and supporting health-promoting activities. The details of the cooperation will be specified in future agreements.
We are confident that this partnership will strengthen our position in the medical industry and enable further development of innovative technologies for health.

The Medical Research Agency (ABM) has just announced its plan for 2025 (ABM plan-dzialalnosci/2025/2929). In its Activity Plan for 2025, it identifies key areas that respond to the contemporary challenges of medicine and healthcare. We are proud to emphasize that our existing projects and innovative technologies precisely support the implementation of these ambitious goals, contributing to the improvement of healthcare quality in Poland.

ABM plans to analyze the impact of the widespread use of continuous glucose monitoring (CGM) devices on the effectiveness of diabetes treatment.

Proacta is already ahead of these initiatives, offering pilot models of CGM systems that are being successfully tested in hospitals. Our solutions enable detailed analysis of CGM data, which supports better treatment adjustment and improves patients’ quality of life.

The ABM open competition for research experiments provides for the development of new medical procedures and the optimization of patient pathways across a wide range of conditions, including cardiovascular, neurological, autoimmune, and cancerous diseases.

Proacta has extensive experience in analyzing data related to medical procedures. Our analytical tools allow for an in-depth assessment of the effectiveness of diagnostic and therapeutic procedures, making us a natural partner for initiatives of this type.

The ABM plan includes launching a competition for clinical trials aimed at identifying and evaluating new therapeutic indications for medicinal products. The goal of these trials is to develop new standards of treatment, diagnosis, or rehabilitation for chronic, autoimmune, and cancerous diseases.

Proacta already offers products that redefine treatment and diagnostic standards. Our solutions are based on the latest clinical research, which is in line with ABM’s mission in Poland.